Home Cart Sign in  
Chemical Structure| 1627503-67-6 Chemical Structure| 1627503-67-6

Structure of LDN-214117
CAS No.: 1627503-67-6

Chemical Structure| 1627503-67-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LDN-214117 is a potent and selective ALK2 inhibitor with IC50 of 22 nM with > 100 fold selectivity for ALK5, and also inhibits BMP6 (IC50=100 nM).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LDN-214117

CAS No. :1627503-67-6
Formula : C25H29N3O3
M.W : 419.52
SMILES Code : COC1=C(OC)C(OC)=CC(C2=C(C)N=CC(C3=CC=C(N4CCNCC4)C=C3)=C2)=C1
MDL No. :MFCD28168043
InChI Key :BHUXVRVMMYAXKN-UHFFFAOYSA-N
Pubchem ID :91754554

Safety of LDN-214117

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • ALK2

    ALK2, IC50:24 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 1, 10, 100 μM 4 and 24 hours Evaluate the cytotoxicity of LDN-214117, showing low cytotoxicity. PMC4191596
QCTB-R059 cells 8.27 µM 8 days Evaluate the inhibitory effect of LDN-214117 on ACVR1 wild-type DIPG cells, showing a GI50 of 8.27 µM. PMC6509210
SU-DIPG-VI cells 5.83 µM 8 days Evaluate the inhibitory effect of LDN-214117 on ACVR1 wild-type DIPG cells, showing a GI50 of 5.83 µM. PMC6509210
SU-DIPG-IV cells 6.23 µM 8 days Evaluate the inhibitory effect of LDN-214117 on ACVR1 G328V mutant DIPG cells, showing a GI50 of 6.23 µM. PMC6509210
HSJD-DIPG-007 cells 1.57 µM 8 days Evaluate the inhibitory effect of LDN-214117 on ACVR1 R206H mutant DIPG cells, showing a GI50 of 1.57 µM. PMC6509210
HEK293T cells 1 nM to 10 μM Overnight Evaluate the inhibitory effect of LDN-214117 on TGF-β1-induced transcriptional activity, IC50 approximately 16.4 μM. PMC4191596
C2C12 cells 1 nM to 10 μM Overnight Evaluate the inhibitory effect of LDN-214117 on BMP6-induced transcriptional activity, IC50 approximately 100 nM. PMC4191596
HUVECs 20 μM 24 hours LDN-214117 significantly increased the intercellular exchange efficacy of T-AgNPs and R-AgNPs from HUVEC to PC3-GFP cells PMC9937035
PC-3 cells 20 μM 24 hours LDN-214117 significantly increased the intercellular exchange efficacy of T-AgNPs and R-AgNPs PMC9937035
C2C12 cells 21nM-10μM 30 minutes To distinguish ALK2 ligand-mediated signaling from ALK3 and ALK1 ligand-mediated signaling PMC6710826

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD.SCID mice HSJD-DIPG-007 orthotopic xenograft model Oral 25 mg/kg Daily administration for 28 days Evaluate the therapeutic effect of LDN-214117 in ACVR1 R206H mutant DIPG model, showing significantly extended survival compared to controls (75 days vs 61 days). PMC6509210
Balb/c mice 4T1 breast tumor model Intratumoral injection 200 μM (20 μL) Once daily for 5 days LDN-214117 significantly increased the accumulation and vascular penetration distance of iRGD-Liposome and iRGD-AgNPs in tumor tissue PMC9937035

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.38mL

0.48mL

0.24mL

11.92mL

2.38mL

1.19mL

23.84mL

4.77mL

2.38mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories